The Experts below are selected from a list of 180 Experts worldwide ranked by ideXlab platform
Claudio Borghi - One of the best experts on this subject based on the ideXlab platform.
-
effect of Lactotripeptides isoleucine proline proline valine proline proline on blood pressure and arterial stiffness changes in subjects with suboptimal blood pressure control and metabolic syndrome a double blind randomized crossover clinical trial
Metabolic Syndrome and Related Disorders, 2016Co-Authors: Arrigo F G Cicero, M Rosticci, Claudio Borghi, Alessandro Colletti, Marcella Cagnati, Riccardo Urso, Marina Giovannini, Sergio DaddatoAbstract:Abstract Background: Lactotripeptides (LTPs) have a mild antihypertensive effect in hypertensive subjects. The main aim of our clinical trial was to test if LTPs could have some influence on blood pressure (BP) and related hemodynamic parameters in a sample of outpatients affected by metabolic syndrome. Methods: A randomized, double-blind, placebo-controlled, crossover clinical trial was conducted in a group of 40 nonsmoking volunteers with metabolic syndrome. The treatment periods were 4 weeks long and were separated by a 4-week washout period. The dietary supplementation was made by daily administration of LTPs from casein, 10.2 mg/day, and compared with placebo. Results: During the LTP treatment, patients experienced a significant mean decrease in systolic BP (SBP; −3.4 ± 4.4 mmHg, P = 0.041), diastolic BP (DBP; −3.1 ± 3.2 mmHg, P = 0.049), and pulse wave velocity (PWV; −0.7 ± 0.3 m/sec, P = 0.001). After LTP treatment, delta SBP, DBP, and PP were all significantly improved (P < 0.01 for all) compared ...
-
Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical
Metabolic Syndrome and Related Disorders, 2015Co-Authors: Arrigo F G Cicero, Claudio Borghi, Martina Rosticci, Alessandro Colletti, Marcella Cagnati, Riccardo Urso, Marina Giovannini, Sergio D'addatoAbstract:Abstract Background: Lactotripeptides (LTPs) have a mild antihypertensive effect in hypertensive subjects. The main aim of our clinical trial was to test if LTPs could have some influence on blood pressure (BP) and related hemodynamic parameters in a sample of outpatients affected by metabolic syndrome. Methods: A randomized, double-blind, placebo-controlled, crossover clinical trial was conducted in a group of 40 nonsmoking volunteers with metabolic syndrome. The treatment periods were 4 weeks long and were separated by a 4-week washout period. The dietary supplementation was made by daily administration of LTPs from casein, 10.2 mg/day, and compared with placebo. Results: During the LTP treatment, patients experienced a significant mean decrease in systolic BP (SBP; −3.4 ± 4.4 mmHg, P = 0.041), diastolic BP (DBP; −3.1 ± 3.2 mmHg, P = 0.049), and pulse wave velocity (PWV; −0.7 ± 0.3 m/sec, P = 0.001). After LTP treatment, delta SBP, DBP, and PP were all significantly improved (P
-
do the Lactotripeptides isoleucine proline proline and valine proline proline reduce systolic blood pressure in european subjects a meta analysis of randomized controlled trials
American Journal of Hypertension, 2013Co-Authors: Arrigo F G Cicero, F Aubin, Veronique Azaisbraesco, Claudio BorghiAbstract:BA CKgr oUnD The milk-derived peptides isoleucine–proline–proline (IPP) and valine– proline– proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations. MethoDS A meta-analysis was conducted in accord with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) requirements, to assess the effect of IPP and VPP on SBP in Europeans, and to explore some determinants of this effect. Ninety-one publications on the effect of IPP and VPP on SBP in Europeans were identified, and 14 trials with 15 sets of data (n = 1,306) met the inclusion criteria for the meta-analysis. A random-effects model (using the restricted maximum likelihood (REML) estimator) was used for the analysis. Although not all individual trials showed a statistically significant effect of IPP or VPP in reducing SBP, the combination of all data for the two peptides yielded a statistically significantly greater effect for IPP/VPP than for placebo. The decrease in SBP with IPP/VPP was 1.28 mm Hg (95% CI, –2.09 t o –0.48, P = 0.0017) and the decrease in diastolic BP (DBP) was 0.59 mm Hg (95% CI, –1.18 to –0.01, P = 0.047). There was no evidence in the meta-analysis of any publication bias or of heterogeneity (P = 0.13). Among other features, a significant effect was seen for age, with each additional year of age reducing the effect on SBP by 0.09 mm Hg . This might be related to isolated systolic hypertension, a condition often encountered in the elderly, who may be poorly responsive to first-line treatments for hypertension. ConClUSIon The peptides IPP and VPP are effective in moderately reducing SBP in European subjects, as is known for Asian populations. These two peptides could therefore have a role in controlling blood pressure (BP), a prospect that merits their further study.
-
Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
American Journal of Hypertension, 2013Co-Authors: Arrigo F G Cicero, F Aubin, Veronique Azais-braesco, Claudio BorghiAbstract:BA CKgr oUnD The milk-derived peptides isoleucine–proline–proline (IPP) and valine– proline– proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations. MethoDS A meta-analysis was conducted in accord with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) requirements, to assess the effect of IPP and VPP on SBP in Europeans, and to explore some determinants of this effect. Ninety-one publications on the effect of IPP and VPP on SBP in Europeans were identified, and 14 trials with 15 sets of data (n = 1,306) met the inclusion criteria for the meta-analysis. A random-effects model (using the restricted maximum likelihood (REML) estimator) was used for the analysis. Although not all individual trials showed a statistically significant effect of IPP or VPP in reducing SBP, the combination of all data for the two peptides yielded a statistically significantly greater effect for IPP/VPP than for placebo. The decrease in SBP with IPP/VPP was 1.28 mm Hg (95% CI, –2.09 t o –0.48, P = 0.0017) and the decrease in diastolic BP (DBP) was 0.59 mm Hg (95% CI, –1.18 to –0.01, P = 0.047). There was no evidence in the meta-analysis of any publication bias or of heterogeneity (P = 0.13). Among other features, a significant effect was seen for age, with each additional year of age reducing the effect on SBP by 0.09 mm Hg . This might be related to isolated systolic hypertension, a condition often encountered in the elderly, who may be poorly responsive to first-line treatments for hypertension. ConClUSIon The peptides IPP and VPP are effective in moderately reducing SBP in European subjects, as is known for Asian populations. These two peptides could therefore have a role in controlling blood pressure (BP), a prospect that merits their further study.
-
predictors of the short term effect of isoleucine proline proline valine proline proline Lactotripeptides from casein on office and ambulatory blood pressure in subjects with pharmacologically untreated high normal blood pressure or first degree hype
Clinical and Experimental Hypertension, 2012Co-Authors: Arrigo F G Cicero, M Rosticci, Maddalena Veronesi, S Bacchelli, Enrico Strocchi, Alienor Ferroni, Claudio BorghiAbstract:Our aim was to evaluate the predictors of Isoleucine–Proline–Proline/Valine–Proline–Proline (IPP–VPP) Lactotripeptides (LTPs) antihypertensive effect in the context of a short-term large double-blind randomized clinical trial involving 164 pharmacologically untreated subjects in primary prevention for cardiovascular disease. When compared with the baseline, office systolic blood pressure (SBP) (−3.42 mm Hg, P < .001) and diastolic blood pressure (DBP) (−2.35 mm Hg, P < .001) significantly decreased, in the LTP-treated patients only. No significant change in predictors during the study of ambulatory blood pressure measurement (ABPM) parameters was observed. A short-term supplementation with LTPs significantly improves the office SBP and DBP, especially in male subjects. The main predictor of LTP antihypertensive effect was the baseline BP.
Arrigo F G Cicero - One of the best experts on this subject based on the ideXlab platform.
-
Nutraceuticals Active on Blood Pressure
Handbook of Nutraceuticals for Clinical Use, 2018Co-Authors: Arrigo F G Cicero, Alessandro CollettiAbstract:Several natural compounds have shown in clinical trials to exert some positive effects on blood pressure. This chapter will resume indication, active dosages, and safety information about Beetroot and organic nitrates, Calcium, Cocoa and dark chocolate, Coenzyme Q10, Ω-3 Polyunsaturated Fatty Acids (EPA/DHA), Garlic, L-arginine, Lactotripeptides, Lycopene, Magnesiun, Melatonin, Pycnogenol, Potassium, Probiotics, Resveratrol, Vitamin C and D.
-
effect of Lactotripeptides isoleucine proline proline valine proline proline on blood pressure and arterial stiffness changes in subjects with suboptimal blood pressure control and metabolic syndrome a double blind randomized crossover clinical trial
Metabolic Syndrome and Related Disorders, 2016Co-Authors: Arrigo F G Cicero, M Rosticci, Claudio Borghi, Alessandro Colletti, Marcella Cagnati, Riccardo Urso, Marina Giovannini, Sergio DaddatoAbstract:Abstract Background: Lactotripeptides (LTPs) have a mild antihypertensive effect in hypertensive subjects. The main aim of our clinical trial was to test if LTPs could have some influence on blood pressure (BP) and related hemodynamic parameters in a sample of outpatients affected by metabolic syndrome. Methods: A randomized, double-blind, placebo-controlled, crossover clinical trial was conducted in a group of 40 nonsmoking volunteers with metabolic syndrome. The treatment periods were 4 weeks long and were separated by a 4-week washout period. The dietary supplementation was made by daily administration of LTPs from casein, 10.2 mg/day, and compared with placebo. Results: During the LTP treatment, patients experienced a significant mean decrease in systolic BP (SBP; −3.4 ± 4.4 mmHg, P = 0.041), diastolic BP (DBP; −3.1 ± 3.2 mmHg, P = 0.049), and pulse wave velocity (PWV; −0.7 ± 0.3 m/sec, P = 0.001). After LTP treatment, delta SBP, DBP, and PP were all significantly improved (P < 0.01 for all) compared ...
-
Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical
Metabolic Syndrome and Related Disorders, 2015Co-Authors: Arrigo F G Cicero, Claudio Borghi, Martina Rosticci, Alessandro Colletti, Marcella Cagnati, Riccardo Urso, Marina Giovannini, Sergio D'addatoAbstract:Abstract Background: Lactotripeptides (LTPs) have a mild antihypertensive effect in hypertensive subjects. The main aim of our clinical trial was to test if LTPs could have some influence on blood pressure (BP) and related hemodynamic parameters in a sample of outpatients affected by metabolic syndrome. Methods: A randomized, double-blind, placebo-controlled, crossover clinical trial was conducted in a group of 40 nonsmoking volunteers with metabolic syndrome. The treatment periods were 4 weeks long and were separated by a 4-week washout period. The dietary supplementation was made by daily administration of LTPs from casein, 10.2 mg/day, and compared with placebo. Results: During the LTP treatment, patients experienced a significant mean decrease in systolic BP (SBP; −3.4 ± 4.4 mmHg, P = 0.041), diastolic BP (DBP; −3.1 ± 3.2 mmHg, P = 0.049), and pulse wave velocity (PWV; −0.7 ± 0.3 m/sec, P = 0.001). After LTP treatment, delta SBP, DBP, and PP were all significantly improved (P
-
do the Lactotripeptides isoleucine proline proline and valine proline proline reduce systolic blood pressure in european subjects a meta analysis of randomized controlled trials
American Journal of Hypertension, 2013Co-Authors: Arrigo F G Cicero, F Aubin, Veronique Azaisbraesco, Claudio BorghiAbstract:BA CKgr oUnD The milk-derived peptides isoleucine–proline–proline (IPP) and valine– proline– proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations. MethoDS A meta-analysis was conducted in accord with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) requirements, to assess the effect of IPP and VPP on SBP in Europeans, and to explore some determinants of this effect. Ninety-one publications on the effect of IPP and VPP on SBP in Europeans were identified, and 14 trials with 15 sets of data (n = 1,306) met the inclusion criteria for the meta-analysis. A random-effects model (using the restricted maximum likelihood (REML) estimator) was used for the analysis. Although not all individual trials showed a statistically significant effect of IPP or VPP in reducing SBP, the combination of all data for the two peptides yielded a statistically significantly greater effect for IPP/VPP than for placebo. The decrease in SBP with IPP/VPP was 1.28 mm Hg (95% CI, –2.09 t o –0.48, P = 0.0017) and the decrease in diastolic BP (DBP) was 0.59 mm Hg (95% CI, –1.18 to –0.01, P = 0.047). There was no evidence in the meta-analysis of any publication bias or of heterogeneity (P = 0.13). Among other features, a significant effect was seen for age, with each additional year of age reducing the effect on SBP by 0.09 mm Hg . This might be related to isolated systolic hypertension, a condition often encountered in the elderly, who may be poorly responsive to first-line treatments for hypertension. ConClUSIon The peptides IPP and VPP are effective in moderately reducing SBP in European subjects, as is known for Asian populations. These two peptides could therefore have a role in controlling blood pressure (BP), a prospect that merits their further study.
-
Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
American Journal of Hypertension, 2013Co-Authors: Arrigo F G Cicero, F Aubin, Veronique Azais-braesco, Claudio BorghiAbstract:BA CKgr oUnD The milk-derived peptides isoleucine–proline–proline (IPP) and valine– proline– proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations. MethoDS A meta-analysis was conducted in accord with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) requirements, to assess the effect of IPP and VPP on SBP in Europeans, and to explore some determinants of this effect. Ninety-one publications on the effect of IPP and VPP on SBP in Europeans were identified, and 14 trials with 15 sets of data (n = 1,306) met the inclusion criteria for the meta-analysis. A random-effects model (using the restricted maximum likelihood (REML) estimator) was used for the analysis. Although not all individual trials showed a statistically significant effect of IPP or VPP in reducing SBP, the combination of all data for the two peptides yielded a statistically significantly greater effect for IPP/VPP than for placebo. The decrease in SBP with IPP/VPP was 1.28 mm Hg (95% CI, –2.09 t o –0.48, P = 0.0017) and the decrease in diastolic BP (DBP) was 0.59 mm Hg (95% CI, –1.18 to –0.01, P = 0.047). There was no evidence in the meta-analysis of any publication bias or of heterogeneity (P = 0.13). Among other features, a significant effect was seen for age, with each additional year of age reducing the effect on SBP by 0.09 mm Hg . This might be related to isolated systolic hypertension, a condition often encountered in the elderly, who may be poorly responsive to first-line treatments for hypertension. ConClUSIon The peptides IPP and VPP are effective in moderately reducing SBP in European subjects, as is known for Asian populations. These two peptides could therefore have a role in controlling blood pressure (BP), a prospect that merits their further study.
Martina Rosticci - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical
Metabolic Syndrome and Related Disorders, 2015Co-Authors: Arrigo F G Cicero, Claudio Borghi, Martina Rosticci, Alessandro Colletti, Marcella Cagnati, Riccardo Urso, Marina Giovannini, Sergio D'addatoAbstract:Abstract Background: Lactotripeptides (LTPs) have a mild antihypertensive effect in hypertensive subjects. The main aim of our clinical trial was to test if LTPs could have some influence on blood pressure (BP) and related hemodynamic parameters in a sample of outpatients affected by metabolic syndrome. Methods: A randomized, double-blind, placebo-controlled, crossover clinical trial was conducted in a group of 40 nonsmoking volunteers with metabolic syndrome. The treatment periods were 4 weeks long and were separated by a 4-week washout period. The dietary supplementation was made by daily administration of LTPs from casein, 10.2 mg/day, and compared with placebo. Results: During the LTP treatment, patients experienced a significant mean decrease in systolic BP (SBP; −3.4 ± 4.4 mmHg, P = 0.041), diastolic BP (DBP; −3.1 ± 3.2 mmHg, P = 0.049), and pulse wave velocity (PWV; −0.7 ± 0.3 m/sec, P = 0.001). After LTP treatment, delta SBP, DBP, and PP were all significantly improved (P
-
Predictors of the Short-Term Effect of Isoleucine–Proline–Proline/Valine–Proline–Proline Lactotripeptides from Casein on Office and Ambulatory Blood Pressure in Subjects with Pharmacologically Untreated High-Normal Blood Pressure or First-Degree Hype
Clinical and Experimental Hypertension, 2012Co-Authors: Arrigo F G Cicero, Maddalena Veronesi, Enrico Strocchi, Martina Rosticci, Alienor Ferroni, Stefano Bacchelli, Claudio BorghiAbstract:Our aim was to evaluate the predictors of Isoleucine–Proline–Proline/Valine–Proline–Proline (IPP–VPP) Lactotripeptides (LTPs) antihypertensive effect in the context of a short-term large double-blind randomized clinical trial involving 164 pharmacologically untreated subjects in primary prevention for cardiovascular disease. When compared with the baseline, office systolic blood pressure (SBP) (−3.42 mm Hg, P < .001) and diastolic blood pressure (DBP) (−2.35 mm Hg, P < .001) significantly decreased, in the LTP-treated patients only. No significant change in predictors during the study of ambulatory blood pressure measurement (ABPM) parameters was observed. A short-term supplementation with LTPs significantly improves the office SBP and DBP, especially in male subjects. The main predictor of LTP antihypertensive effect was the baseline BP.
-
Lactotripeptides effect on office and 24 h ambulatory blood pressure blood pressure stress response pulse wave velocity and cardiac output in patients with high normal blood pressure or first degree hypertension a randomized double blind clinical tri
Hypertension Research, 2011Co-Authors: Arrigo F G Cicero, Maddalena Veronesi, S Bacchelli, B Gerocarni, Martina Rosticci, E Strocchi, Claudio BorghiAbstract:Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial
-
Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical
Hypertension Research, 2011Co-Authors: Arrigo F G Cicero, Maddalena Veronesi, Enrico Strocchi, Martina Rosticci, Stefano Bacchelli, Beatrice Gerocarni, Claudio BorghiAbstract:Contrasting data partially support a certain antihypertensive efficacy of Lactotripeptides (LTPs) derived from enzymatic treatment of casein hydrolysate. Our aim was to evaluate this effect on a large number of hemodynamic parameters. We conducted a prospective double-blind randomized clinical trial, which included 52 patients affected by high-normal blood pressure (BP) or first-degree hypertension. We investigated the effect of a 6-week treatment with the LTPs isoleucine–proline–proline and valine–proline–proline at 3 mg per day, assumed to be functional food, on office BP, 24-h ambulatory BP monitoring (ABPM) values, stress-induced BP increase and cardiac output-related parameters. In the LTP-treated subjects, we observed a significant reduction in office systolic BP (SBP; −5±8 mm Hg, P =0.013) and a significant improvement in pulse wave velocity (PWV; −0.66±0.81 m s^−1, P =0.001; an instrumental biomarker of vascular rigidity). No effect on 24-h ABPM parameters and BP reaction to stress was observed from treatment with the combined LTPs. LTPs, but not placebo, were associated with a mild but significant change in the stroke volume (SV), SV index (markers of cardiac flow), the acceleration index (ACI) and velocity index (VI) (markers of cardiac contractility). No effect was observed on parameters related to fluid dynamics or vascular resistance. LTPs positively influenced the office SBP, PWV, SV, SV index, ACI and VI in patients with high-normal BP or first-degree hypertension.
Maddalena Veronesi - One of the best experts on this subject based on the ideXlab platform.
-
predictors of the short term effect of isoleucine proline proline valine proline proline Lactotripeptides from casein on office and ambulatory blood pressure in subjects with pharmacologically untreated high normal blood pressure or first degree hype
Clinical and Experimental Hypertension, 2012Co-Authors: Arrigo F G Cicero, M Rosticci, Maddalena Veronesi, S Bacchelli, Enrico Strocchi, Alienor Ferroni, Claudio BorghiAbstract:Our aim was to evaluate the predictors of Isoleucine–Proline–Proline/Valine–Proline–Proline (IPP–VPP) Lactotripeptides (LTPs) antihypertensive effect in the context of a short-term large double-blind randomized clinical trial involving 164 pharmacologically untreated subjects in primary prevention for cardiovascular disease. When compared with the baseline, office systolic blood pressure (SBP) (−3.42 mm Hg, P < .001) and diastolic blood pressure (DBP) (−2.35 mm Hg, P < .001) significantly decreased, in the LTP-treated patients only. No significant change in predictors during the study of ambulatory blood pressure measurement (ABPM) parameters was observed. A short-term supplementation with LTPs significantly improves the office SBP and DBP, especially in male subjects. The main predictor of LTP antihypertensive effect was the baseline BP.
-
Predictors of the Short-Term Effect of Isoleucine–Proline–Proline/Valine–Proline–Proline Lactotripeptides from Casein on Office and Ambulatory Blood Pressure in Subjects with Pharmacologically Untreated High-Normal Blood Pressure or First-Degree Hype
Clinical and Experimental Hypertension, 2012Co-Authors: Arrigo F G Cicero, Maddalena Veronesi, Enrico Strocchi, Martina Rosticci, Alienor Ferroni, Stefano Bacchelli, Claudio BorghiAbstract:Our aim was to evaluate the predictors of Isoleucine–Proline–Proline/Valine–Proline–Proline (IPP–VPP) Lactotripeptides (LTPs) antihypertensive effect in the context of a short-term large double-blind randomized clinical trial involving 164 pharmacologically untreated subjects in primary prevention for cardiovascular disease. When compared with the baseline, office systolic blood pressure (SBP) (−3.42 mm Hg, P < .001) and diastolic blood pressure (DBP) (−2.35 mm Hg, P < .001) significantly decreased, in the LTP-treated patients only. No significant change in predictors during the study of ambulatory blood pressure measurement (ABPM) parameters was observed. A short-term supplementation with LTPs significantly improves the office SBP and DBP, especially in male subjects. The main predictor of LTP antihypertensive effect was the baseline BP.
-
Lactotripeptides effect on office and 24 h ambulatory blood pressure blood pressure stress response pulse wave velocity and cardiac output in patients with high normal blood pressure or first degree hypertension a randomized double blind clinical tri
Hypertension Research, 2011Co-Authors: Arrigo F G Cicero, Maddalena Veronesi, S Bacchelli, B Gerocarni, Martina Rosticci, E Strocchi, Claudio BorghiAbstract:Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial
-
Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical
Hypertension Research, 2011Co-Authors: Arrigo F G Cicero, Maddalena Veronesi, Enrico Strocchi, Martina Rosticci, Stefano Bacchelli, Beatrice Gerocarni, Claudio BorghiAbstract:Contrasting data partially support a certain antihypertensive efficacy of Lactotripeptides (LTPs) derived from enzymatic treatment of casein hydrolysate. Our aim was to evaluate this effect on a large number of hemodynamic parameters. We conducted a prospective double-blind randomized clinical trial, which included 52 patients affected by high-normal blood pressure (BP) or first-degree hypertension. We investigated the effect of a 6-week treatment with the LTPs isoleucine–proline–proline and valine–proline–proline at 3 mg per day, assumed to be functional food, on office BP, 24-h ambulatory BP monitoring (ABPM) values, stress-induced BP increase and cardiac output-related parameters. In the LTP-treated subjects, we observed a significant reduction in office systolic BP (SBP; −5±8 mm Hg, P =0.013) and a significant improvement in pulse wave velocity (PWV; −0.66±0.81 m s^−1, P =0.001; an instrumental biomarker of vascular rigidity). No effect on 24-h ABPM parameters and BP reaction to stress was observed from treatment with the combined LTPs. LTPs, but not placebo, were associated with a mild but significant change in the stroke volume (SV), SV index (markers of cardiac flow), the acceleration index (ACI) and velocity index (VI) (markers of cardiac contractility). No effect was observed on parameters related to fluid dynamics or vascular resistance. LTPs positively influenced the office SBP, PWV, SV, SV index, ACI and VI in patients with high-normal BP or first-degree hypertension.
-
hemodynamic effects of Lactotripeptides from casein hydrolysate in mediterranean normotensive subjects and patients with high normal blood pressure a randomized double blind crossover clinical trial
Journal of Medicinal Food, 2010Co-Authors: Arrigo F G Cicero, M Rosticci, Maddalena Veronesi, S Bacchelli, Enrico Strocchi, Camilla Melegari, Elisa Grandi, Claudio BorghiAbstract:Abstract Contrasting data partially support a certain antihypertensive efficacy of Lactotripeptides derived from enzymatic treatment of casein hydrolysate. We carried out a randomized, double-blind, crossover clinical study to investigate the antihypertensive efficacy of a short-term treatment with Lactotripeptides in Mediterranean subjects with normal or high-normal blood pressure (BP). We consecutively enrolled 55 untreated subjects (men:women = 30:25), 40.3 ± 9.8 years old, with normal or high-normal BP. After 4 weeks of dietary standardization, they were allocated to treatment with a fruit juice containing 3 mg of added Ile-Pro-Pro/Val-Pro-Pro Lactotripeptides or with placebo for 4 weeks. After a 4-week washout period, they were then assigned to the alternative treatment for a further period of 4 weeks. Overall, no significant difference has been observed in office BP comparing baseline data with those posttreatment. Repeating the analysis by basal BP level, a mild but significant reduction in systoli...
B Gerocarni - One of the best experts on this subject based on the ideXlab platform.
-
Lactotripeptides effect on office and 24 h ambulatory blood pressure blood pressure stress response pulse wave velocity and cardiac output in patients with high normal blood pressure or first degree hypertension a randomized double blind clinical tri
Hypertension Research, 2011Co-Authors: Arrigo F G Cicero, Maddalena Veronesi, S Bacchelli, B Gerocarni, Martina Rosticci, E Strocchi, Claudio BorghiAbstract:Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial
-
Blood pressure lowering effect of Lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials
Journal of Human Hypertension, 2011Co-Authors: A F G Cicero, B Gerocarni, L Laghi, C BorghiAbstract:The oral assumption of Lactotripeptides Valine–Proline–Proline (VPP) and Isoleucine–Proline–Proline (IPP) as nutraceuticals or functional foods is supposed to improve blood pressure (BP) control by angiotensin-converting enzyme-inhibition. However, data derived from clinical trials have reached conflicting conclusions. To perform a meta-analysis of placebo-controlled clinical trials evaluating the anti-hypertensive effect of Lactotripeptides assumed as nutraceuticals or functional foods. Trials identified using a defined search strategy in PubMed were included in the meta-analysis, and their pooled effect was estimated with a random effects model, weighting for the inverse of the variance. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A total of 18 trials have been identified, the clinical data of which have been clearly reported. Pooled effect of peptides was a reduction of −3.73 mm Hg (95% CI: −6.70, −1.76) for systolic blood pressure (SBP) and 1.97 mm Hg (95% CI: −3.85, −0.64) for diastolic blood pressure (DBP). The effect was more evident in Asian patients (SBP=−6.93 mm Hg (95% CI: −10.95, −2.94); DBP=−3.98 mm Hg(95% CI: −5.38, −2.44)) than in Caucasian ones (SBP=−1.17 mm Hg (95% CI: −2.82, 0.72); DBP=−0.52 mm Hg (95% CI: −1.39, 0.13)), and apparently not related to age, baseline BP values, dose of Lactotripeptides assumed or length of the treatment. VPP and IPP Lactotripeptides assumed as functional foods may significantly reduce SBP particularly in Asian subjects. The relevance of this findings in other ethnicities or associated with different dietary pattern should to be further investigated.
